Compare
Booz Allen Hamilton Holding Corp vs Genpact Ltd vs FTI Consulting, Inc vs Astrana Health, Inc.
| Latest fiscal year | Booz Allen Hamilton Holding Corp BAH | Genpact Ltd G | FTI Consulting, Inc FCN | Astrana Health, Inc. ASTH |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.22B | $5.08B | $3.79B | $3.18B |
| Revenue growth (YoY) | -6.4% | +6.6% | +2.4% | +56.4% |
| Gross margin | 52.7% (computed) | 36.0% | 32.1% | n/a |
| Operating margin | 9.2% | 14.8% | 10.3% | 2.5% |
| Net margin | 7.6% | 10.9% | 7.1% | 0.7% |
| Net income | $851.00M | $552.49M | $270.87M | $22.49M |
| EPS (Diluted) | $6.90 | $3.13 | $8.24 | $0.46 |
| Operating cash flow | $1.04B | $812.86M | $152.13M | $114.60M |
| Free cash flow | $951.00M | $734.65M | $93.60M | $104.49M |
| Cash & equivalents | $728.00M | $853.84M | $265.09M | $429.47M |
| Total assets | $7.12B | $5.84B | $3.49B | $2.22B |
| Total liabilities | $6.01B | $3.29B | $1.76B | $1.66B |
| Shareholders' equity | $1.10B | $2.55B | $1.73B | $779.29M |
| Return on year-end equity | 77.0% | 21.7% | 15.6% | 2.9% |
| Shares outstanding | 120.34M | 170.34M | 30.86M | 48.89M |
Revenue, most recent five fiscal years
| Fiscal year | Booz Allen Hamilton Holding Corp | Genpact Ltd | FTI Consulting, Inc | Astrana Health, Inc. |
|---|---|---|---|---|
| Latest | $11.22B Ended 2026-03-31 | $5.08B Ended 2025-12-31 | $3.79B Ended 2025-12-31 | $3.18B Ended 2025-12-31 |
| 1 year earlier | $11.98B Ended 2025-03-31 | $4.77B Ended 2024-12-31 | $3.70B Ended 2024-12-31 | $2.03B Ended 2024-12-31 |
| 2 years earlier | $10.66B Ended 2024-03-31 | $4.48B Ended 2023-12-31 | $3.49B Ended 2023-12-31 | $1.39B Ended 2023-12-31 |
| 3 years earlier | $9.26B Ended 2023-03-31 | $4.37B Ended 2022-12-31 | $3.03B Ended 2022-12-31 | $1.14B Ended 2022-12-31 |
| 4 years earlier | $8.36B Ended 2022-03-31 | $4.02B Ended 2021-12-31 | $2.78B Ended 2021-12-31 | $773.91M Ended 2021-12-31 |